BMJ Open protocol targets moxibustion evidence for PCOS across fertility and metabolic endpoints
Polycystic ovary syndrome remains one of the most common endocrinopathies in women of reproductive age, and the search for adjunctive therapies has pushed moxibustion into a space where fertility care and metabolic medicine intersect. The BMJ Open protocol by Xu, Wang, Hu, Lv, Zhang, Yang, Huang, and Zhou is designed to answer a simple but clinically difficult question: does moxibustion improve reproduction and metabolism in patients with PCOS, and can it do so with an acceptable safety profile?
The protocol is built around a recognized problem in the field. Moxibustion is already used in assisted reproduction settings and in attempts to address metabolic abnormalities associated with PCOS, yet the evidence base remains unsettled because high-quality randomized data have been limited. In a condition where anovulation, endocrine disruption, and metabolic dysfunction often travel together, a therapy that could improve ovulation while also shifting hormone profiles or insulin-related markers would carry obvious bedside appeal. Still, clinical plausibility does not replace a structured evidence review. This protocol exists to separate traditional use from demonstrable effect.
Fertility endpoints sit at the center of the planned review
The review will search electronic databases from inception to May 2021, including The Cochrane Library, PubMed, EMBASE, Chinese Biomedical Literature, VIP, and China National Knowledge Infrastructure. Ongoing studies will also be sought in the Chinese Clinical Trial Registry Center and Clinical Trials. That broad search strategy matters because much of the available work on moxibustion in PCOS has circulated in regional literature and may never have entered the mainstream reproductive endocrinology conversation.
Randomized controlled trials will be included, along with the first period of randomized cross-over trials. The primary outcomes are ovulation rate, pregnancy rate, and sex hormone levels. Those endpoints reflect the two faces of PCOS management: restoring ovulatory function and correcting the hormonal milieu that drives irregular cycles, subfertility, and persistent endocrine disruption. In practical terms, ovulation rate may reveal whether moxibustion influences follicular development and release, while pregnancy rate addresses the more clinically concrete question of whether those endocrine changes translate into conception.
Hormone measures are equally important because PCOS is not defined by infertility alone. Hyperandrogenism, ovulatory dysfunction, and broader reproductive hormone imbalance are central to the syndrome’s biology. A therapy that only improves symptoms without altering this axis would be less compelling than one that meaningfully changes sex hormone levels in parallel with reproductive outcomes.
Metabolic measures and safety outcomes broaden the clinical frame
The protocol does not confine itself to fertility alone. Secondary outcomes include changes in clinical symptoms and metabolic indicators, total effective rate, and the incidence of side effects and adverse events. This is the right framing for a syndrome in which reproductive dysfunction often coexists with insulin resistance, weight-related metabolic strain, and longer-term cardiometabolic risk.
By including metabolic indicators, the review acknowledges that PCOS is a systemic disorder rather than a narrow gynecologic problem. Any intervention that improves ovulation but leaves metabolic abnormalities untouched may offer only partial benefit. Conversely, an approach that affects both reproductive and metabolic endpoints could become more relevant to integrative care pathways, especially in patients who seek nonpharmacologic options or who are already receiving fertility treatment.
Safety remains a necessary part of the review question. Complementary therapies are sometimes discussed as inherently gentle, but this assumption is not evidence. The planned assessment of side effects and adverse events will be essential for clinicians who need to know whether any reproductive or endocrine benefit comes with tolerability concerns. A therapy used alongside ovulation induction or assisted reproduction has to be judged not only by whether it works, but by whether it complicates care.
The review will use two independent reviewers for study selection and data extraction, with risk of bias assessment conducted in parallel. Before formal meta-analysis, heterogeneity among the included studies will be evaluated. That step is especially important because moxibustion studies may vary by technique, treatment schedule, comparator choice, and patient characteristics. Without careful handling of heterogeneity, pooled estimates can become too blunt to guide practice.
Evidence grading will determine whether pooled findings can inform practice
RevMan V.5.3 will be used for the statistical synthesis, and the GRADE approach will be applied to judge the quality of evidence. This is the right finish line for a protocol that aims to move beyond descriptive enthusiasm. A pooled result is only as useful as the certainty behind it, and GRADE offers a structured way to judge whether the evidence is strong enough to support clinical confidence or still too fragile to guide decision-making.
The protocol does not promise an answer in advance. It lays out the route to one. If the included randomized trials are sufficiently consistent and methodologically sound, the review could clarify whether moxibustion has measurable value for ovulation, pregnancy, hormone regulation, and metabolic change in PCOS. If the studies are small, biased, or too heterogeneous to combine meaningfully, the review may instead define the limits of the current literature with more precision than any single trial could.
No ethical approval is required because the project is a systematic review rather than a direct intervention study. Dissemination is planned through a peer-reviewed journal or conference presentation. For clinicians, the most useful outcome may not be a dramatic claim of efficacy, but a sharper estimate of what the existing PCOS moxibustion literature can and cannot support — especially once trial quality, adverse events, and metabolic outcomes are weighed alongside fertility endpoints.